The Anemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Anemia: An Overview
According to World Health Organization (WHO) (n.d.), Anaemia is a condition in which the number of red blood cells or the hemoglobin concentration is lower than normal. If there are too few or abnormal red blood cells, or not enough hemoglobin, there will be a decreased capacity of the blood to carry oxygen to the body’s tissues. Approximately 25% of people worldwide have anemia. Iron deficiency, the most common cause, is responsible for 50% of all anemias.
Current oral treatments are not well tolerated and negatively impact the gut microbiome of patients. Many conventional oral iron supplements are based on ferrous iron or ferric iron forms, which have been associated with quite a number of gastrointestinal side effects, including disrupting the gut microbiome.
The current emerging landscape for Anemia mainly comprising of Phase II and Phase III candidate drugs. The key players for phase II and III clinical development are Nemesis, MegaPro Biomedical, Akebia Therapeutics, GlaxoSmithKline, and others. The launch of the emerging therapies is expected to change the treatment dynamics.
Anemia Market Key Facts
-
According to World Health Organization (2011), it is estimated that roughly 43% of children, 38% of pregnant women, 29% of non-pregnant women, and 29% of all women of reproductive age had anemia.
-
According to data from The German Society for Haematology and Medical Oncology (2014), the average prevalence of iron deficiency in Europe was 5 to 10 percent. Whilst diagnosed in 4-8% of children between 13-15 years of age – at 20% – the highest prevalence was seen in women during their reproductive years.
-
According to data of the Ministry of Health, Labor and Welfare (Japan; 2015), there was approximately one woman among 10 who had iron-deficiency anemia. If restrict this data to women having their menstruation, there was one woman among five who has anemia.
-
According to the Global Burden of Disease Study 2016, iron deficiency anemia is 1 of the 5 leading causes of years lived with disability burden and is the first cause in women.
The Anemia Market Size is anticipated to increase during the forecast period owing to the rising cases in 7MM. A better understanding of disease and development in therapies is also expected to boost the growth of the therapeutic market.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Anemia market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.
The report gives a thorough detail of the Anemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Anemia Epidemiology
The epidemiology section covers insights into the historical and current Anemia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Anemia Epidemiology Segmentation
-
Total prevalent cases of Anemia
-
Gender-specific cases of Anemia
-
Severity-specific cases of Anemia
-
Age-specific cases of Anemia
-
Total diagnosed and treated cases of Anemia
Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anemia market or expected to get launched in the market during the study period. The analysis covers Anemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Anemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Some of the key companies in the Anemia Market include:
-
Akebia Therapeutics
-
GlaxoSmithKline
-
Nemysis
-
MegaPro Biomedical
Get the PDF Sample of the Report:- Anemia Therapeutics Market
Anemia Therapies covered in the report include:
-
Vadadustat
-
Daprodustat
-
IHAT-02
-
MPB-1514
And many others
Get More Detailed Insights into the Emerging Therapies & Key Companies:- Chronic Insomnia Therapeutics Landscape
Table of Content
1. Key Insights
2. Executive Summary
3. Anemia Competitive Intelligence Analysis
4. Anemia Market Overview at a Glance
5. Anemia Disease Background and Overview
6. Anemia Patient Journey
7. Anemia Epidemiology and Patient Population
8. Anemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Anemia Unmet Needs
10. Key Endpoints of Anemia Treatment
11. Anemia Marketed Products
12. Anemia Emerging Therapies
13. Anemia Seven Major Market Analysis
14. Attribute Analysis
15. Anemia Market Outlook (7 major markets)
16. Anemia Access and Reimbursement Overview
17. KOL Views on the Anemia Market.
18. Anemia Market Drivers
19. Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/anemia-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market
